La chaîne d'options affiche les données clés des options sur actions de Axion Ven à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Axion Ven..

Axion Ven (OTC:AXNVF) Stock, Chaîne d'Options

Axion Ventures Inc is an investment issuer with majority ownership in online video gaming and other IT sectors. The principal activities of the Group are principally engaged in game software development, game operation, provision of outsourcing services, software license and software training. The geographical presence of the company in Canada, China and Rest of the world.

AXION VENTURES INC by Axion Ventures Inc.

Axion Ventures Inc

Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.16 by 37.5 percent. The company reported quarterly sales of $159.300 million which beat the analyst consensus estimate of $157.566 million by 1.10 percent. This is a 11.69 percent increase over sales of $142.625 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

JAMF

Jamf Holding Q3 2024 Adj. EPS $0.10 Misses $0.16 Estimate, Sales $159.300M Beat $157.566M Estimate

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6.67 percent. The company reported quarterly sales of $58.555 million which beat the analyst consensus estimate of $53.808 million by 8.82 percent. This is a 12.39K percent increase over sales of $469.000 thousand the same period last year.

IOVA

Iovance Biotherapeutics Q3 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $58.555M Beat $53.808M Estimate

Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 68.18 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $43.73 million which missed the analyst consensus estimate of $45.31 million by 3.50 percent. This is a 1.58 percent increase over sales of $43.05 million the same period last year.

CMBM

Cambium Networks Q3 Adj $(0.14) Beats $(0.17) Estimate, Sales $43.73M Miss $45.31M Estimate

LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) sees Q4 sales of $57.000 million-58.000 million vs $57.34 million estimate.

Guidance

LFMD

LifeMD Sees Q4 Sales $57.000M-58.000M vs $57.34M Est

Savers Value Vllage Narrows FY24 Adj. Net Income From $82M-$96M To $81M-$86M

Contracts

Bloom Energy And Quanta Computer Announced A Major Expansion Of An Existing Agreement To Power The Production Of Critical Hardware  Serving The AI Industry; Terms Not Disclosed

Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.37) by 16.22 percent. The company reported quarterly sales of $446.52 million which beat the analyst consensus estimate of $430.37 million by 3.75 percent. This is a 17.95 percent decrease over sales of $544.21 million the same period last year.

Unity Software Q3 2024 GAAP EPS $(0.31) Beats $(0.37) Estimate, Sales $446.52M Beat $430.37M Estimate

Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent.

MNMD

Mind Medicine Q3 2024 GAAP EPS $(0.27) Beats $(0.28) Estimate

Nu Skin Sees Q4 Adj. EPS $0.19-$0.29 vs $0.28 Est., Revenue $410M-$445M vs $455.83M Est.; Sees 2024 Adj. EPS $0.65-$0.75 vs $0.77 Est., Revenue $1.7B-$1.73B vs $1.75B Est.

Air Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AL#NYSE">AL</a>) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $0.79 by 58.23 percent. The company reported quarterly sales of $690.16 million which beat the analyst consensus estimate of $676.82 million by 1.97 percent. This is a 4.67 percent increase over sales of $659.36 million the same period last year.

Air Lease Q3 2024 Adj EPS $1.25 Beats $0.79 Estimate, Sales $690.16M Beat $676.82M Estimate

MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 7.69 percent. The company reported quarterly sales of $62.93 million which beat the analyst consensus estimate of $40.14 million by 56.78 percent. This is a 19.82 percent increase over sales of $52.52 million the same period last year.

MP Materials Q3 2024 Adj EPS $(0.12) Beats $(0.13) Estimate, Sales $62.93M Beat $40.14M Estimate

QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.32 by 165.63 percent. The company reported quarterly sales of $727.10 million which beat the analyst consensus estimate of $642.10 million by 13.24 percent. This is a 2.27 percent decrease over sales of $744.00 million the same period last year.

QDEL

QuidelOrtho Q3 2024 Adj EPS $0.85 Beats $0.32 Estimate, Sales $727.10M Beat $642.10M Estimate

Yelp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.42 by 33.33 percent. The company reported quarterly sales of $360.00 million which missed the analyst consensus estimate of $360.39 million by 0.11 percent. This is a 4.31 percent increase over sales of $345.12 million the same period last year.

YELP

Yelp Q3 2024 Adj EPS $0.56 Beats $0.42 Estimate, Sales $360.00M Miss $360.39M Estimate

FLYW

Flywire Corp Sees FY24 Ad. EBITDA $76-$80M; Q4 Adj. EBITDA $15M-$19M.

Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.19) by 78.15 percent. The company reported quarterly sales of $41.673 million which beat the analyst consensus estimate of $36.597 million by 13.87 percent. This is a 7.68 percent decrease over sales of $45.140 million the same period last year.

ARCT

Arcturus Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(1.19) Estimate, Sales $41.673M Beat $36.597M Estimate

RDFN

Redfin Sees Q4 Revenue $237M-$247M V

Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) reported quarterly earnings of $2.62 per share. This is a 1039.13 percent increase over earnings of $0.23 per share from the same period last year. The company reported $69.96 million in sales this quarter. This is a 71.28 percent increase over sales of $40.84 million the same period last year.

SEZL

Sezzle Q3 EPS $2.62 Up From $0.23 YoY, Sales $69.96M Up From $40.84M YoY

Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. The company reported quarterly sales of $220.90 million which missed the analyst consensus estimate of $238.37 million by 7.33 percent. This is a 0.59 percent increase over sales of $219.61 million the same period last year.

WEST

Westrock Coffee Q3 2024 Adj EPS $(0.05) Beats $(0.06) Estimate, Sales $220.90M Miss $238.37M Estimate

Flywire Corp Sees FY24 Revenue $495M-$503M Vs $486.071M Est; Sees Q4 Revenue $121M-$129M.

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.14 by 21.43 percent. The company reported quarterly sales of $430.100 million which missed the analyst consensus estimate of $440.954 million by 2.46 percent. This is a 13.77 percent decrease over sales of $498.772 million the same period last year.

Comments

Axion Ven

Axion Ven (AXNVF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL